Shopping Cart

Pulmonary Arterial Hypertension-Pipeline Review, H1 2016

SKU
GMDHC7707IDB
READ MORE
USD 2,000
Single User License
USD 2,000
Site License
USD 4,000
Corporate User License
USD 6,000

Summary

Global Markets Direct's, 'Pulmonary Arterial Hypertension-Pipeline Review, H1 2016', provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the ther

READ MORE
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Summary

Global Markets Direct's, 'Pulmonary Arterial Hypertension-Pipeline Review, H1 2016', provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension

The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects

The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Pulmonary Arterial Hypertension Overview 9

Therapeutics Development 10

Pipeline Products for Pulmonary Arterial Hypertension-Overview 10

Pipeline Products for Pulmonary Arterial Hypertension-Comparative Analysis 11

Pulmonary Arterial Hypertension-Therapeutics under Development by Companies 12

Pulmonary Arterial Hypertension-Therapeutics under Investigation by Universities/Institutes 16

Pulmonary Arterial Hypertension-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Pulmonary Arterial Hypertension-Products under Development by Companies 20

Pulmonary Arterial Hypertension-Products under Investigation by Universities/Institutes 24

Pulmonary Arterial Hypertension-Companies Involved in Therapeutics Development 25

APT Therapeutics, Inc. 25

Arena Pharmaceuticals, Inc. 26

Asahi Kasei Pharma Corp. 27

Ascendis Pharma A/S 28

Bial-Portela & Ca, S.A. 29

Bristol-Myers Squibb Company 30

Carolus Therapeutics, Inc. 31

Celsion Corporation 32

Complexa, Inc. 33

Corridor Pharmaceuticals Inc. 34

Cytokinetics, Inc. 35

Eli Lilly and Company 36

F. Hoffmann-La Roche Ltd. 37

Gilead Sciences, Inc. 38

Insmed Incorporated 39

INVENT Pharmaceuticals, Inc. 40

Johnson & Johnson 41

Kowa Company, Ltd. 42

Mallinckrodt Plc 43

Mezzion Pharma Co. Ltd. 44

miRagen Therapeutics, Inc. 45

Morphogen-IX Limited 46

Nippon Kayaku Co., Ltd. 47

Nippon Shinyaku Co., Ltd. 48

Novartis AG 49

Peloton Therapeutics, Inc. 50

PharmaIN Corporation 51

PhaseBio Pharmaceuticals, Inc. 52

Pluristem Therapeutics Inc. 53

Proteo, Inc. 54

Pulmokine, Inc. 55

Reata Pharmaceuticals, Inc. 56

Respira Therapeutics, Inc. 57

Selten Pharma, Inc 58

Silence Therapeutics Plc 59

SteadyMed Therapeutics, Inc. 60

Suda Ltd 61

Toray Industries, Inc. 62

Pulmonary Arterial Hypertension-Therapeutics Assessment 63

Assessment by Monotherapy Products 63

Assessment by Target 64

Assessment by Mechanism of Action 68

Assessment by Route of Administration 71

Assessment by Molecule Type 73

Drug Profiles 75

Antibody for Pulmonary Arterial Hypertension-Drug Profile 75

Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension-Drug Profile 76

APT-602-Drug Profile 77

bardoxolone methyl-Drug Profile 78

beraprost sodium ER-Drug Profile 81

beraprost sodium SR-Drug Profile 82

BIA-51058-Drug Profile 83

BMP-9-Drug Profile 84

CT-2009-Drug Profile 85

CXA-10-Drug Profile 86

Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension-Drug Profile 87

fasudil-Drug Profile 88

imatinib mesylate-Drug Profile 89

INS-1009-Drug Profile 92

INV-240-Drug Profile 93

JNJ-26993135-Drug Profile 94

lisuride-Drug Profile 95

MFC-001-Drug Profile 97

MFC-002-Drug Profile 98

nitric oxide-Drug Profile 99

Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension-Drug Profile 102

Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension-Drug Profile 103

PB-1046-Drug Profile 104

PB-1120-Drug Profile 106

pitavastatin NP-Drug Profile 107

PK-10453-Drug Profile 108

PK-10571-Drug Profile 109

PLX-PAD-Drug Profile 110

PT-2977-Drug Profile 114

QCC-374-Drug Profile 115

R-190-Drug Profile 116

ralinepag-Drug Profile 118

RT-234-Drug Profile 120

selexipag-Drug Profile 121

selonsertib-Drug Profile 123

sirolimus albumin-bound-Drug Profile 124

Small Molecule for Pulmonary Arterial Hypertension-Drug Profile 126

Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction-Drug Profile 127

Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension-Drug Profile 128

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension-Drug Profile 129

Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension-Drug Profile 130

Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension-Drug Profile 131

SPI-054-Drug Profile 132

SPI-183-Drug Profile 133

SUD-004-Drug Profile 134

Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction-Drug Profile 135

Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension-Drug Profile 136

tacrolimus-Drug Profile 137

tadalafil-Drug Profile 138

tiprelestat-Drug Profile 140

tocilizumab-Drug Profile 143

TR-422-Drug Profile 147

treprostinil-Drug Profile 148

treprostinil diolamine-Drug Profile 149

TXA-127-Drug Profile 150

ubenimex-Drug Profile 153

udenafil-Drug Profile 154

Pulmonary Arterial Hypertension-Recent Pipeline Updates 156

Pulmonary Arterial Hypertension-Dormant Projects 185

Pulmonary Arterial Hypertension-Discontinued Products 188

Pulmonary Arterial Hypertension-Product Development Milestones 189

Featured News & Press Releases 189

Appendix 197

Methodology 197

Coverage 197

Secondary Research 197

Primary Research 197

Expert Panel Validation 197

Contact Us 197

Disclaimer 198


List Of Figure

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2016 14

Number of Products under Development for Pulmonary Arterial Hypertension-Comparative Analysis, H1 2016 15

Number of Products under Development by Companies, H1 2016 16

Number of Products under Investigation by Universities/Institutes, H1 2016 20

Comparative Analysis by Late Stage Development, H1 2016 21

Comparative Analysis by Clinical Stage Development, H1 2016 22

Comparative Analysis by Early Stage Products, H1 2016 23

Assessment by Monotherapy Products, H1 2016 67

Number of Products by Top 10 Targets, H1 2016 68

Number of Products by Stage and Top 10 Targets, H1 2016 68

Number of Products by Top 10 Mechanism of Actions, H1 2016 72

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 72

Number of Products by Routes of Administration, H1 2016 75

Number of Products by Stage and Routes of Administration, H1 2016 75

Number of Products by Top 10 Molecule Types, H1 2016 77

Number of Products by Stage and Top 10 Molecule Types, H1 2016 77


List Of Table

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2016 14

Number of Products under Development for Pulmonary Arterial Hypertension-Comparative Analysis, H1 2016 15

Number of Products under Development by Companies, H1 2016 17

Number of Products under Development by Companies, H1 2016 (Contd..1) 18

Number of Products under Development by Companies, H1 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2016 20

Comparative Analysis by Late Stage Development, H1 2016 21

Comparative Analysis by Clinical Stage Development, H1 2016 22

Comparative Analysis by Early Stage Development, H1 2016 23

Products under Development by Companies, H1 2016 24

Products under Development by Companies, H1 2016 (Contd..1) 25

Products under Development by Companies, H1 2016 (Contd..2) 26

Products under Development by Companies, H1 2016 (Contd..3) 27

Products under Investigation by Universities/Institutes, H1 2016 28

Pulmonary Arterial Hypertension-Pipeline by APT Therapeutics, Inc., H1 2016 29

Pulmonary Arterial Hypertension-Pipeline by Arena Pharmaceuticals, Inc., H1 2016 30

Pulmonary Arterial Hypertension-Pipeline by Asahi Kasei Pharma Corp., H1 2016 31

Pulmonary Arterial Hypertension-Pipeline by Ascendis Pharma A/S, H1 2016 32

Pulmonary Arterial Hypertension-Pipeline by Bial-Portela & Ca, S.A., H1 2016 33

Pulmonary Arterial Hypertension-Pipeline by Bristol-Myers Squibb Company, H1 2016 34

Pulmonary Arterial Hypertension-Pipeline by Carolus Therapeutics, Inc., H1 2016 35

Pulmonary Arterial Hypertension-Pipeline by Celsion Corporation, H1 2016 36

Pulmonary Arterial Hypertension-Pipeline by Complexa, Inc., H1 2016 37

Pulmonary Arterial Hypertension-Pipeline by Corridor Pharmaceuticals Inc., H1 2016 38

Pulmonary Arterial Hypertension-Pipeline by Cytokinetics, Inc., H1 2016 39

Pulmonary Arterial Hypertension-Pipeline by Eli Lilly and Company, H1 2016 40

Pulmonary Arterial Hypertension-Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 41

Pulmonary Arterial Hypertension-Pipeline by Gilead Sciences, Inc., H1 2016 42

Pulmonary Arterial Hypertension-Pipeline by Insmed Incorporated, H1 2016 43

Pulmonary Arterial Hypertension-Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 44

Pulmonary Arterial Hypertension-Pipeline by Johnson & Johnson, H1 2016 45

Pulmonary Arterial Hypertension-Pipeline by Kowa Company, Ltd., H1 2016 46

Pulmonary Arterial Hypertension-Pipeline by Mallinckrodt Plc, H1 2016 47

Pulmonary Arterial Hypertension-Pipeline by Mezzion Pharma Co. Ltd., H1 2016 48

Pulmonary Arterial Hypertension-Pipeline by miRagen Therapeutics, Inc., H1 2016 49

Pulmonary Arterial Hypertension-Pipeline by Morphogen-IX Limited, H1 2016 50

Pulmonary Arterial Hypertension-Pipeline by Nippon Kayaku Co., Ltd., H1 2016 51

Pulmonary Arterial Hypertension-Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 52

Pulmonary Arterial Hypertension-Pipeline by Novartis AG, H1 2016 53

Pulmonary Arterial Hypertension-Pipeline by Peloton Therapeutics, Inc., H1 2016 54

Pulmonary Arterial Hypertension-Pipeline by PharmaIN Corporation, H1 2016 55

Pulmonary Arterial Hypertension-Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 56

Pulmonary Arterial Hypertension-Pipeline by Pluristem Therapeutics Inc., H1 2016 57

Pulmonary Arterial Hypertension-Pipeline by Proteo, Inc., H1 2016 58

Pulmonary Arterial Hypertension-Pipeline by Pulmokine, Inc., H1 2016 59

Pulmonary Arterial Hypertension-Pipeline by Reata Pharmaceuticals, Inc., H1 2016 60

Pulmonary Arterial Hypertension-Pipeline by Respira Therapeutics, Inc., H1 2016 61

Pulmonary Arterial Hypertension-Pipeline by Selten Pharma, Inc, H1 2016 62

Pulmonary Arterial Hypertension-Pipeline by Silence Therapeutics Plc, H1 2016 63

Pulmonary Arterial Hypertension-Pipeline by SteadyMed Therapeutics, Inc., H1 2016 64

Pulmonary Arterial Hypertension-Pipeline by Suda Ltd, H1 2016 65

Pulmonary Arterial Hypertension-Pipeline by Toray Industries, Inc., H1 2016 66

Assessment by Monotherapy Products, H1 2016 67

Number of Products by Stage and Target, H1 2016 69

Number of Products by Stage and Mechanism of Action, H1 2016 73

Number of Products by Stage and Route of Administration, H1 2016 76

Number of Products by Stage and Molecule Type, H1 2016 78

Pulmonary Arterial Hypertension Therapeutics-Recent Pipeline Updates, H1 2016 160

Pulmonary Arterial Hypertension-Dormant Projects, H1 2016 189

Pulmonary Arterial Hypertension-Dormant Projects (Contd..1), H1 2016 190

Pulmonary Arterial Hypertension-Dormant Projects (Contd..2), H1 2016 191

Pulmonary Arterial Hypertension-Discontinued Products, H1 2016 192

To know more information on Purchase by Section, please send a mail to

Products

Pulmonary Arterial Hypertension Therapeutic Products under Development, Key Players in Pulmonary Arterial Hypertension Therapeutics, Pulmonary Arterial Hypertension Pipeline Overview, Pulmonary Arterial Hypertension Pipeline, Pulmonary Arterial Hypertension Pipeline Assessment

Companies

APT Therapeutics, Inc. Arena Pharmaceuticals, Inc. Asahi Kasei Pharma Corp. Ascendis Pharma A/S Bial-Portela & Ca, S.A. Bristol-Myers Squibb Company Carolus Therapeutics, Inc. Celsion Corporation Complexa, Inc. Corridor Pharmaceuticals Inc. Cytokinetics, Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. Insmed Incorporated INVENT Pharmaceuticals, Inc. Johnson & Johnson Kowa Company, Ltd. Mallinckrodt Plc Mezzion Pharma Co. Ltd. miRagen Therapeutics, Inc. Morphogen-IX Limited Nippon Kayaku Co., Ltd. Nippon Shinyaku Co., Ltd. Novartis AG Peloton Therapeutics, Inc. PharmaIN Corporation PhaseBio Pharmaceuticals, Inc. Pluristem Therapeutics Inc. Proteo, Inc. Pulmokine, Inc. Reata Pharmaceuticals, Inc. Respira Therapeutics, Inc. Selten Pharma, Inc Silence Therapeutics Plc SteadyMed Therapeutics, Inc. Suda Ltd Toray Industries, Inc.

Brand Description
History Color sit amet, consectetur adipiscing elit. In gravida pellentesque ligula, vel eleifend turpis blandit vel. Nam quis lorem ut mi mattis ullamcorper ac quis dui. Vestibulum et scelerisque ante, eu sodales mi. Nunc tincidunt tempus varius. Integer ante dolor, suscipit non faucibus a, scelerisque vitae sapien.